TheraRadar
Clinical-Stage Companies / Shanghai Shengdi Pharmaceutical

Shanghai Shengdi Pharmaceutical

Pre-Approval PRO BETA
9
Total Trials
5
Phase 3
3
Phase 2
5
Recruiting
133
Score

Pipeline by Phase

Phase 3
5
Phase 2
3
Phase 1
3

Therapeutic Focus

Advanced Cervical Cancer Locally Advanced Gastric or Gastroesophageal Junction Cancer For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions Solid Tumors

Clinical Trials (9)

NCT07168200 Phase 3 RECRUITING

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Started: 10/17/2025

NCT07275723 Phase 3 RECRUITING

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions

Started: 11/14/2025

NCT07275814 Phase 3 RECRUITING

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

Started: 11/17/2025

NCT07522151 Phase 3 NOT YET RECRUITING

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Started: 5/1/2026

NCT06237257 Phase 2 ACTIVE NOT RECRUITING

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Started: 3/20/2024

NCT06335355 Phase 2 NOT YET RECRUITING

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Started: 3/1/2024

NCT07231211 Phase 1 RECRUITING

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Started: 11/20/2025

NCT07123376 Phase 1 COMPLETED

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

Started: 6/5/2024

NCT06657560 Phase 1 COMPLETED

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

Started: 10/14/2024

Drug Candidates

SHR-1316 Injection Cisplatin Injection Carboplatin Injection Paclitaxel Injection SHR-1316 Placebo Injection Adebrelimab plus S-1 and oxaliplatin Adebrelimab blank preparation plus S-1 and oxaliplatin. HRS-9231 Injection Gadobutrol Injection SHR-4610 Injection
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 7/3/2025
Trials (12 months): 5
Completed Trials: 2
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.